Hualan Biological Engineering Inc(002007) vaccine Co., Ltd
Initial public offering and listing on GEM
Announcement of issuance results
Sponsor (lead underwriter): Huatai United Securities Co., Ltd
hot tip
The application of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. (hereinafter referred to as “Hualan vaccine” and “issuer”) for the initial public offering of 40.01 million RMB common shares (A shares) (hereinafter referred to as “this offering”) and listing on the gem has been examined and approved by the GEM Listing Committee of Shenzhen Stock Exchange, It has been approved to register by China Securities Regulatory Commission (hereinafter referred to as “CSRC”) (zjxk [2022] No. 2). The sponsor (lead underwriter) of this offering is Huatai United Securities Co., Ltd. (hereinafter referred to as “sponsor (lead underwriter)” or “Huatai United Securities”). The issuer’s stock is abbreviated as “Hualan vaccine” and the stock code is “301207”.
This issuance adopts directional placement to strategic investors (hereinafter referred to as “strategic placement”) Offline inquiry placement to qualified offline investors (hereinafter referred to as “offline issuance”) and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts in Shenzhen market (hereinafter referred to as “online issuance”).
The issuer and the sponsor (lead underwriter) negotiated and determined that the issue price is 56.88 yuan / share, and the number of shares issued is 40.01 million. All of them are new shares without transfer of old shares. The issuing price of this offering shall not exceed the median and weighted average of offline investors’ quotation after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund established through public offering after excluding the highest quotation The enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds are 62.0000 yuan / share, so the relevant subsidiaries of the sponsor need not participate in the follow-up investment.
According to the issuing price, the relevant subsidiaries of the recommendation institution do not participate in the strategic placement. The strategic placement object of this issuance is the special asset management plan of the issuer’s senior managers and core employees. The final number of strategic placement is 4001000 shares, accounting for 10.00% of this issuance. The difference between the initial number of strategic placements and the final number of strategic placements is 2000500 shares transferred back to offline issuance.
After the callback of strategic placement and before the launch of online and offline callback mechanism, the number of offline issuance was 29207500 shares, accounting for 81.11% of the number of this issuance after deducting the final strategic placement, and the number of online issuance was 6801500 shares, accounting for 18.89% of the number of this issuance after deducting the final strategic placement.
According to the callback mechanism announced in the announcement of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. initial public offering and listing on the gem, since the initial effective subscription multiple on the Internet is 9611.90384 times, more than 100 times, the issuer and the sponsor (lead underwriter) decided to start the callback mechanism to adjust the scale of offline and online issuance, After deducting the final strategic placement, 20.00% (rounded up to an integral multiple of 500 shares, i.e. 7202000 shares) of the number of shares issued this time will be transferred back from offline to online.
After the callback mechanism was launched, the final number of shares issued offline was 22005500, accounting for 61.11% of the number of shares issued this time after deducting the final strategic placement, and the final number of shares issued online was 14003500, accounting for 38.89% of the number of shares issued this time after deducting the final strategic placement. After the call back, the winning rate of this online issuance is 0.0214201484%, and the effective subscription multiple is 4668.50173 times.
The online and offline subscription and payment work of this offering has been completed on February 10, 2022 (T + 2). 1、 Statistics of new share subscription
The sponsor (lead underwriter) made statistics on the subscription of new shares issued online and offline in this strategic placement according to the payment of strategic investors and the data provided by Shenzhen Stock Exchange and Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. (hereinafter referred to as “Shenzhen Branch of China Clearing”), and the results are as follows:
(I) strategic placement
The issuing price of this offering shall not exceed the median and weighted average of offline investors’ quotation after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund established through public offering after excluding the highest quotation The enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds, whichever is lower, is 62.0000 yuan / share.
The strategic placement of this issuance is the special asset management plan for the issuer’s senior managers and core employees. Huatai Hualan vaccine home No. 1 gem employee stock ownership collective asset management plan. According to the issuing price, the relevant subsidiaries of the sponsor will not participate in the strategic placement. The final strategic placement number of this issuance is 4001000 shares,
Accounting for 10.00% of the number of this issue.
As of January 26, 2022 (T-4), strategic investors have paid their subscription funds in full and on time. According to the relevant agreements in the strategic investor placement agreement for initial public offering of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. signed by the issuer and strategic investors, the strategic placement results of this issuance are determined as follows:
Serial number name of strategic investor number of allocated shares (shares) amount allocated (yuan) sales restriction period
1 Huatai Hualan vaccine home No. 1 gem 4001000 227576880.00 12-month ESOP collective asset management plan
Total 4001000 227576880.00-
(II) online subscription of new shares
1. Number of shares subscribed by online investors (shares): 13898134
2. Subscription amount paid by online investors (yuan): 790525861.92
3. Number of online investors giving up subscription (shares): 105366
4. Subscription amount abandoned by online investors (yuan): 5993218.08
(III) offline subscription of new shares
1. Number of shares subscribed by offline investors (shares): 22005500
2. Subscription amount paid by offline investors (yuan): 1251672840.00
3. Number of offline investors giving up subscription (shares): 0
4. Subscription amount abandoned by offline investors (yuan): 0.00
2、 Offline proportional restriction
The offline issuance part adopts the proportional sales restriction method, and the offline investors shall promise that the sales restriction period of 10% (rounded up) of the number of shares allocated to them is 6 months from the date of the issuer’s initial public offering and listing.
That is, among the shares allocated to each placing object, 90% of the shares are sold indefinitely and can be circulated from the date when the issued shares are listed and traded on the Shenzhen Stock Exchange; The sales restriction period of 10% of the shares is 6 months, and the sales restriction period starts from the date when the issued shares are listed and traded on the Shenzhen Stock Exchange.
When offline investors participate in the preliminary inquiry and quotation and offline purchase, they do not need to fill in the arrangement of the restricted sale period for the placing objects under their management. Once the quotation is made, it is deemed to accept the arrangement of the online restricted sale period disclosed in this announcement.
In this offering, the number of shares whose offline proportion is restricted for 6 months is 2202660 shares, accounting for 10.01% of the total offline issuance and 5.51% of the total public offering.
3、 Underwriting by the recommendation institution (lead underwriter)
The number of shares abandoned by online and offline investors is underwritten by the sponsor (lead underwriter). The number of shares underwritten by the sponsor (lead underwriter) is 105366 shares, and the underwriting amount is 5993218.08 yuan. The proportion of the number of shares underwritten by the sponsor (lead underwriter) in the number of shares issued this time is 0.2633%.
On February 14, 2022 (T + 4), the recommendation institution (lead underwriter) transferred the underwriting funds and the funds raised from offline and online issuance to the issuer after deducting the recommendation and underwriting fee. The issuer will submit an application for share registration to CSDCC Shenzhen Branch and register the underwritten shares to the securities account designated by the sponsor (lead underwriter). 4、 Contact information of sponsor (lead underwriter)
If online and offline investors have any questions about the issuance results announced in this announcement, please contact the sponsor (lead underwriter) of this issuance. The specific contact information is as follows:
Sponsor (lead underwriter): Huatai United Securities Co., Ltd
Contact: stock capital market department
Tel: 010-56839453
Contact email: [email protected].
Contact address: 6 / F, block a, Fengming international building, No. 22 Fengsheng Hutong, Xicheng District, Beijing
Issuer: Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. sponsor (lead underwriter): Huatai United Securities Co., Ltd. February 14, 2022 (there is no text on this page, which is the seal page of the announcement on the results of initial public offering and listing on the gem of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd
Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. (there is no text on this page, which is the seal page of the announcement on the results of initial public offering and listing on the gem of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd.)
Huatai United Securities Co., Ltd
